Igenomix portfolio includes pioneering genetic tests to help reproductive-health professionals to analyse and treat their patients before, during and after their reproductive journey.
Vitrolife delivers innovative, high-quality products to ensure optimal care at every stage of the IVF journey, from error prevention and gamete handling to embryo evaluation and cryopreservation.
Latest financial report
Fourth quarter & full year report 2025
We achieved strong sales growth in local currencies for the final quarter of the year, despite significant macroeconomic headwinds. Sales for the fourth quarter increased by 6% in local currencies excluding discontinued business.
Press Releases
03 February 2026
20 January 2026
Invitation to Vitrolife Group's presentation of the fourth quarter and full year report 2025
16 December 2025
Financial Calendar
-
12 Mar 2026
DNB Carnegie Healthcare Conference 2026 in Stockholm
-
25 Mar 2026
Nordic-American Healthcare Conference
-
26 Mar 2026
Annual and sustainability report 2025
Careers
The Vitrolife Group offers an attractive workplace with an opportunity to work for a higher purpose, a purpose that makes a difference in people’s lives worldwide.
Investor relations
Our aim is to have a strong capital base to enable continued high growth, both organically and through acquisitions. We strive to achieve growth through profitability.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.